Variation in
Summary
A multi-cohort GWAS of acute vasodilator response in PAH identified a locus near SNX29, with functional studies in cells and a hypoxic mouse model supporting a role for SNX29 in modulating vasodilation via reduced store-operated calcium entry and altered endosomal trafficking of SOCE proteins. These findings advance mechanistic understanding of vasodilator-responsive PAH and suggest SNX29 as a potential biomarker or therapeutic target.
Key Findings
- GWAS across national cohorts identified a SNX29-linked variant associated with acute vasodilator response in PAH.
- Functional assays in cell culture and a hypoxic mouse model supported a role for SNX29 in vasodilation.
- Mechanism implicated reduced store-operated calcium entry and altered endosomal trafficking of SOCE proteins.
Clinical Implications
SNX29 may help stratify vasodilator-responsive PAH patients and offers a mechanistic target to enhance vasodilator responsiveness; translational validation could inform precision therapy.
Why It Matters
Links human genetic variation to a mechanistic pathway (SOCE) that determines vasodilator responsiveness in PAH, integrating GWAS with in vitro and in vivo validation.
Limitations
- Abstract does not report effect sizes or independent replication details.
- Clinical utility for patient selection and therapy remains to be prospectively validated.
Future Directions
Replicate associations in independent cohorts, define SNX29-modulating interventions, and prospectively test SNX29 as a predictor of vasodilator responsiveness and outcomes.
Study Information
- Study Type
- Cohort
- Research Domain
- Pathophysiology
- Evidence Level
- III - Observational genetic association study with mechanistic validation
- Study Design
- OTHER